| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.34 |
| 52 Week High | CN¥2.17 |
| 52 Week Low | CN¥1.33 |
| Beta | 0.65 |
| 11 Month Change | -4.09% |
| 3 Month Change | n/a |
| 1 Year Change | -37.79% |
| 33 Year Change | -68.17% |
| 5 Year Change | -43.82% |
| Change since IPO | -49.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 08HH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | 1.5% |
| 1Y | -37.8% | -12.6% | 12.6% |
Return vs Industry: 08HH underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: 08HH underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| 08HH volatility | |
|---|---|
| 08HH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 08HH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 08HH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 39,309 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 08HH fundamental statistics | |
|---|---|
| Market cap | €7.70b |
| Earnings (TTM) | €234.49m |
| Revenue (TTM) | €5.17b |
36.5x
P/E Ratio1.7x
P/S RatioIs 08HH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 08HH income statement (TTM) | |
|---|---|
| Revenue | CN¥40.47b |
| Cost of Revenue | CN¥21.48b |
| Gross Profit | CN¥18.99b |
| Other Expenses | CN¥17.15b |
| Earnings | CN¥1.83b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 46.92% |
| Net Profit Margin | 4.53% |
| Debt/Equity Ratio | 55.0% |
How did 08HH perform over the long term?
See historical performance and comparison